Navigation Links
InspireMD Appoints Robert Ratini as Vice President of Sales and Marketing
Date:4/9/2012

TEL AVIV, Israel, April 9, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced the appointment of Robert Ratini as its Vice President of Sales and Marketing. Mr. Ratini will develop and lead all  global marketing strategies for InspireMD's proprietary stent system technology, MGuard™. Mr. Ratini will join InspireMD full time on June 1, 2012.

Mr. Ratini has over 20 years of experience in leadership roles in the medical device industry. He was previously Director of Marketing at Orbusneich Medical Hoevelaken in the Netherlands. Prior to that, he served as Vice President of Global Marketing and EMEA Sales at Biosensors International, Switzerland, where he established a global sales and marketing department and led the launch of the BioMatrix™ drug eluding stent. His experience also includes positions at Abbott Vascular Europe, CardiacAssist Inc., Europe and Boston Scientific, Switzerland. He also spent 10 years at Haemonetics SA, Switzerland, where his roles included Director of Marketing (Europe), Manager of Product Development, surgical division, and Software Development Engineer. Furthermore, Mr. Ratini has served as an independent business consultant, providing consulting services and advice to medical technology companies in Switzerland and France.

Ofir Paz, Chief Executive Officer and co-founder of InspireMD, commented, "We are pleased to welcome Robert to InspireMD, as he brings a vast array of skills and expertise to our management team. His appointment is a critical step in our efforts to strengthen and expand the sales and marketing infrastructure for MGuard™ and his experience will help us overcome the challenge of establishing MGuard™ as a significant product in the stent market.  We look forward to the strategic contributions and the fresh insights Robert will bring during this exciting time for InspireMD."

"I am very pleased to join InspireMD, as the Company prepares for global commercialization of MGuard™," said Mr. Ratini. "I believe that MGuard™ is an exciting product with the potential of filling a large unmet need and becoming the standard of care for the interventional treatment of Acute MI patients."

Mr. Ratini holds a Master of Computer Sciences from the University of Applied Sciences (HES-SO) in Bienne, Switzerland and a Swiss Federal Diploma of Electronics from Ecole Technique Neuchâtel. In addition, he studied International Marketing at INSEAD in Paris and Management at CQM, Cambridge, USA.

About InspireMD Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2012. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contact:
Michael Rice
Office Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com

Corporate Contact:
Jonina Ohayon
Marketing Director
Email: jonina@inspire-md.com
OTC BB: NSPR
www.inspire-md.com


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Feb. 23, 2017 ITL Limited, ( ASX: ITD ), ... for the half year ended 31 December 2016 compared with the ... presentation can be viewed here . Highlights ... $1.04m; up 104%) Earnings per share of 2.2 ... of $17.5m (Dec 2015: $15.7m; up 11%) Profit ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... replacement options at his office, Antoine Dental Center. Currently, patients can get single ... restrictions may apply, but patients can learn more about these offers by contacting ...
(Date:2/24/2017)... , ... February 24, 2017 , ... An in-depth computational ... the University of Pittsburgh points to eight genes that may explain why susceptibility to ... to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
Breaking Medicine News(10 mins):